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Abstract 
Joint modelling of longitudinal and time-to-event data has received much attention recently. 
Increasingly, extensions to standard joint modelling approaches are being proposed to 
handle complex data structures commonly encountered in applied research. In this paper 
we propose a joint model for hierarchical longitudinal and time-to-event data. Our 
motivating application explores the association between tumor burden and progression-
free survival in non-small cell lung cancer patients. We define tumor burden as a function of 
the sizes of target lesions clustered within a patient. Since a patient may have more than 
one lesion, and each lesion is tracked over time, the data have a three-level hierarchical 
structure: repeated measurements taken at time points (level 1) clustered within lesions 
(level 2) within patients (level 3). We jointly model the lesion-specific longitudinal 
trajectories and patient-specific risk of death or disease progression by specifying novel 
association structures that combine information across lower level clusters (e.g. lesions) into 
patient-level summaries (e.g. tumor burden). We provide user-friendly software for fitting 
the model under a Bayesian framework. Lastly, we discuss alternative situations in which 
additional clustering factor(s) occur at a level higher in the hierarchy than the patient-level, 
since this has implications for the model formulation.     
Keywords: longitudinal; survival; joint model; shared parameter model; hierarchical; 
multilevel; cancer 
  
1. Introduction 
In clinical or epidemiological research studies, longitudinal data may be in the form of a 
clinical biomarker that is repeatedly measured over time on a given patient, whilst time-to-
event data may refer to the patient-specific time from a defined origin (e.g. time of 
diagnosis of a disease) until a clinical event of interest such as death or disease progression. 
A common motivation for collecting such data is to explore how changes in the biomarker 
are associated with the occurrence of the event. A rapidly evolving field of statistical 
methodology, known as “joint modelling”, aims to model both the longitudinal and time-to-
event data simultaneously providing several potential benefits over more traditional 
approaches [1–3]. Compared with using the observed biomarker measurements as 
covariates in a time-to-event model, a joint modelling approach can protect against bias due 
to missing data or measurement error in estimating  the association between the value of 
the biomarker and the risk of occurrence of the event [1,4]. Moreover, we can explore the 
associations between more complex aspects of the biomarker trajectory (such as the rate of 
change) and the occurrence of the event. Lastly, we might wish to use the longitudinal 
biomarker data in the development of a “dynamic” risk prediction model, and joint 
modelling approaches lend themselves to this purpose [5,6]. 
The so-called “shared parameter” joint modelling approach consists of two regression 
submodels, one for the longitudinal biomarker measurements (the “longitudinal submodel”) 
and one for the time-to-event outcome (the “event submodel”). Dependence between the 
two submodels is allowed for by assuming that the model for the time-to-event outcome 
includes as predictor some functional form of the patient-specific parameters from the 
longitudinal submodel, commonly referred to as an association structure. In the joint 
modelling literature to date, primary focus has been on a situation in which there is a single 
normally-distributed biomarker measured repeatedly over time for each patient and a 
unique, possibly right-censored, time to a terminating event of interest [4,7]. However, a 
number of extensions have been proposed for the standard shared parameter joint model, 
such as competing risks [8], interval censored event times [9], non-normally distributed 
biomarkers [10], and multiple biomarkers [11].  
Nonetheless, a common aspect of the proposed methodology has been that the longitudinal 
data have a two-level hierarchical structure; longitudinal measurements of the biomarker 
are observed at time points (level 1 of the hierarchy) which are clustered within patients 
(level 2 of the hierarchy). The patient is therefore considered to be the only clustering 
factor.  An example of this data structure is shown in Figure 1a. However, there exist many 
situations in clinical and epidemiological research in which we wish to analyse longitudinal 
and time-to-event data where the longitudinal data component (and potentially also the 
time-to-event component) has a hierarchical structure with clustering factors beyond just 
that of the patient.  
In this paper we describe a joint modelling approach that can be applied to longitudinal and 
time-to-event data with more than one clustering factor. In Section 2 we introduce several 
motivating examples which describe the types of data structures our joint modelling 
approach is intended for. In Sections 3 and 4 we describe the formulation and estimation of 
a joint model that is suitable when an additional clustering factor occurs at a level lower in 
the hierarchy than the patient-level. In Section 5 we describe an application in which we use 
this joint model to explore the association between tumor burden and risk of death or 
disease progression in non-small cell lung cancer (NSCLC) patients undergoing treatment. In 
Section 6 we describe the formulation of the joint model under alternative scenarios in 
which the additional clustering factor occurs at a level higher in the hierarchy than the 
patient-level. In Section 7 we close with a discussion. 
2. Motivating examples 
2.1 Tumor burden and progression-free survival in non-small cell lung cancer 
In our primary motivating example interest lies in exploring the relationship between tumor 
burden and the risk of death or disease progression in patients with non-small cell lung 
cancer (NSCLC). After a patient initiates treatment the size of each tumor lesion is measured 
repeatedly over time in order to assess the effectiveness of treatment and aid clinical 
decision making. Accordingly, for a given patient, we can define the tumor burden as some 
patient-level summary of the sizes of their individual tumor lesions. Given that a patient 
may have more than one lesion, our data consists of a hierarchy in which the longitudinal 
measurements are observed at time points (level 1) which are clustered within a specific 
lesion (level 2) for a given patient (level 3), as represented in Figure 1b. 
Consideration of the multilevel structure of the data is important for several reasons. Firstly, 
the underlying growth trajectories may vary across different lesions, even when those 
lesions are clustered within the same patient. We can allow for between-lesion variation in 
the growth trajectories through the use of lesion-specific, as well as patient-specific, 
parameters in the longitudinal submodel. Equivalently, the introduction of lesion-specific 
parameters in the longitudinal submodel allows us to account for the within-cluster 
correlation of longitudinal measurements made on the same lesion and therefore 
appropriately estimate standard errors. Secondly, the hierarchical structure of the data is a 
key aspect to consider when specifying the form of the association between the longitudinal 
and event processes, something we discuss further in Section 3.3. 
2.2 Visual field progression in glaucoma 
Our second motivating example comes from research on eye disease. In ophthalmology it is 
of interest to use repeated measurements of eye-specific biomarkers to help predict the 
occurrence of disease-specific events. For example, in glaucoma research we may be 
interested in the association between optic nerve head surface depth (ONHSD) and visual 
field progression. Previous studies [12] have used joint models to explore this association by 
treating each eye as independent and modelling the association between the eye-specific 
longitudinal trajectory for ONHSD and the eye-specific event endpoint (visual field 
progression). However, this approach ignores the dependence between measurements 
taken on the two eyes clustered within a patient. Arguably, a more appropriate analysis 
approach would model the correlation between measurements taken on a person’s two 
eyes. Hence, consider a joint modelling approach in which we assume the ONHSD 
measurements are observed at time points (level 1) which are clustered within a specific eye 
(level 2) for a given patient (level 3). We could then explore the association between the 
longitudinal trajectory for ONHSD and a patient-specific endpoint for the time to visual field 
progression. 
2.3 Patients within clinics or the meta-analysis of joint model data 
Our final two motivating examples relate to an alternative data structure in which the 
additional clustering factor occurs at a level which is higher in the hierarchy than the 
patient. One example is where repeated observation times (level 1) exist for patients (level 
2) and those patients are clustered within clinics (level 3). Another example is an individual 
patient data (IPD) meta-analysis where observation times (level 1) are for patients (level 2) 
clustered within randomised clinical trials (level 3) [13]. In both of these examples, we wish 
to include the additional clustering factor (i.e. the clinic or the trial) in our joint modelling 
approach, so that we appropriately allow for the correlation structure. However, because 
the additional clustering factor occurs at a level higher than the patient-level, there are 
different implications for the specification of the joint model association structure 
compared with our previous motivating examples. For this reason we describe a formulation 
of the joint model for this type of data structure separately; in Section 6 of the paper.  
3. Model formulation 
3.1 Longitudinal submodel 
Consider the situation in which we have a three-level hierarchical structure for our 
longitudinal data, where the patient represents the highest level of the hierarchy (in Section 
6 we discuss the situation in which the patient does not represent the highest level of the 
hierarchy). We assume our longitudinal outcome measurements 𝑦𝑖𝑗𝑘 = 𝑦𝑖𝑗(𝑡𝑖𝑗𝑘) are 
obtained  at a set of time points 𝑘 = 1, … , 𝐾𝑖𝑗 which are assumed to be nested within unit 
𝑗 (𝑗 = 1, … , 𝐽𝑖) of the level 2 clustering factor which in turn is nested within patient 𝑖 (𝑖 =
1, … , 𝑁), the level 3 clustering factor. We model the longitudinal outcome in continuous 
time using a generalised linear mixed effects model where we assume 𝑌𝑖𝑗(𝑡) is governed by 
a distribution in the exponential family with expected value 𝜇𝑖𝑗(𝑡) = 𝑔
−1(𝜂𝑖𝑗(𝑡)) for some 
known link function 𝑔(. ). Specific choices of family and link function lead to, for example, 
linear, logistic or Poisson regression. We specify a three-level hierarchical model for the 
linear predictor 
 𝜂𝑖𝑗(𝑡) = 𝑥𝑖𝑗
′ (𝑡)𝛽 + 𝑧𝑖𝑗
′ (𝑡)𝑏𝑖 + 𝑤𝑖𝑗
′ (𝑡)𝑢𝑖𝑗   (1) 
where 𝑥𝑖𝑗(𝑡), 𝑧𝑖𝑗(𝑡), and 𝑤𝑖𝑗(𝑡) are vectors of covariates, possibly time-dependent. The 
vector 𝛽 contains fixed-effect parameters, and 𝑢𝑖𝑗  and 𝑏𝑖 are vectors of level 2 (cluster-
specific) and level 3 (patient-specific) parameters, each assumed to be normally distributed 
with mean zero and unstructured variance-covariance matrix, that is 𝑢𝑖𝑗 ∼ 𝑁(0, 𝛴𝑢) and 
𝑏𝑖 ∼ 𝑁(0, 𝛴𝑏). We assume that 𝑢𝑖𝑗 and 𝑏𝑖 are uncorrelated. 
3.2 Event submodel 
We observe an event time 𝑇𝑖 = 𝑚𝑖𝑛 {𝑇𝑖
∗, 𝐶𝑖}, where 𝑇𝑖
∗ denotes the true event time for 
patient 𝑖 and 𝐶𝑖  denotes the right-censoring time, and define an indicator of observed event 
occurrence 𝑑𝑖 = 𝐼(𝑇𝑖
∗ ≤ 𝐶𝑖). We model the hazard of the event using a proportional 
hazards regression model 
 ℎ𝑖(𝑡) = ℎ0(𝑡)𝑒𝑥𝑝 (𝑣𝑖
′(𝑡)𝛾 + ∑ 𝛼𝑞𝑓𝑞(𝛩𝑖𝑗(𝑡);  𝑗 = 1, … , 𝐽𝑖))
𝑄
𝑞=1    (2) 
where ℎ𝑖(𝑡) is the hazard of the event for patient 𝑖 at time 𝑡, ℎ0(𝑡) is the baseline hazard at 
time 𝑡, 𝑣𝑖(𝑡) is a vector of covariates with an associated vector of fixed-effect parameters 𝛾, 
and ∑ 𝛼𝑞𝑓𝑞(𝛩𝑖𝑗(𝑡);  𝑗 = 1, … , 𝐽𝑖)
𝑄
𝑞=1  forms the “association structure” for the joint model 
which consists of some specified set of functions 𝑓𝑞(. ) applied to the full set of (possibly 
time-varying) parameters from the longitudinal submodel 𝛩𝑖𝑗(𝑡) = {𝛽, 𝑏𝑖 , 𝑢𝑖𝑗 , 𝜇𝑖𝑗(𝑡), 𝜂𝑖𝑗(𝑡)} 
with associated fixed effects 𝛼𝑞 (𝑞 = 1, … , 𝑄). The functions 𝑓𝑞(. ) might each correspond to 
a functional of the longitudinal submodel parameters for a given patient 𝑖and cluster 𝑗, for 
example, the expected value or rate of change in the longitudinal biomarker. Alternatively, 
they might be functions of the longitudinal submodel parameters for a given patient 𝑖  
across all 𝐽𝑖  clusters, representing different methods for combining the level 2 clusters into a 
patient-level summary (as described in the next section). We refer to the fixed effects 𝛼𝑞 as 
“association parameters” since they quantify the magnitude of the association between 
aspects of the longitudinal process and the event process. In the next section we describe 
the variety of ways in which the association structure for the joint model can be specified.  
3.3 Association structures for patient-level summaries 
Given that the event time 𝑇𝑖 is measured at the patient-level, the patient represents the 
level of the hierarchy at which our primary interest lies for understanding the association 
between the longitudinal and event processes. Accordingly, we wish to formulate a model 
that captures the association between the longitudinal and event processes at any given 
time 𝑡 in a meaningful way at the patient-level. A decision is required about how 
information from the level 2 clustering factor (that is, the clustering factor between the 
patient-level and the observation-level) is used in the formulation of the association 
structure.  
Since the number of level 2 units may differ for each patient (i.e. it isn’t necessarily the case 
that 𝐽𝑖 = 𝐽𝑖′  for all 𝑖 ≠  𝑖
′) we must combine the information in the level 2 units into some 
patient-level time-specific summary. Obvious choices for a patient-level summary measure 
are likely to be the summation, average, maximum or minimum taken across the level 2 
units within patient 𝑖. That is  
 𝑓𝑞(𝛩𝑖𝑗(𝑡);  𝑗 = 1, … , 𝐽𝑖) = ∑ 𝜇𝑖𝑗(𝑡) 
𝐽𝑖
𝑗=1   (3) 
 𝑓𝑞(𝛩𝑖𝑗(𝑡);  𝑗 = 1, … , 𝐽𝑖) = 𝐽𝑖
−1 ∑ 𝜇𝑖𝑗(𝑡)
𝐽𝑖
𝑗=1    (4) 
 𝑓𝑞(𝛩𝑖𝑗(𝑡);  𝑗 = 1, … , 𝐽𝑖) = 𝑚𝑎𝑥 (𝜇𝑖𝑗(𝑡);   𝑗 = 1, … , 𝐽𝑖)   (5) 
 𝑓𝑞(𝛩𝑖𝑗(𝑡);  𝑗 = 1, … , 𝐽𝑖) = 𝑚𝑖𝑛 (𝜇𝑖𝑗(𝑡);   𝑗 = 1, … , 𝐽𝑖)  (6) 
The association structure resulting from equation (3) assumes that the hazard of the event 
for patient 𝑖 at time 𝑡 is associated with the sum of the expected values (at time 𝑡) for each 
of the level 2 units clustered within that patient. In contrast, the 𝐽𝑖
−1term in equation (4) 
provides us with the average of the level 2 cluster-specific expected values within patient 𝑖 
rather than their summation alone. Lastly, equations (5) and (6), respectively, assume that 
the hazard of the event for patient 𝑖 at time 𝑡 is associated with the level 2 cluster (within 
patient 𝑖) that has the largest or smallest expected value at time 𝑡. It is possible for more 
than one of these summary functions to be included in a single model (i.e. 𝑄 > 1). 
Moreover, other summary functions are possible but are not described here. 
The most appropriate summary function(s) may be determined based on clinical context, or 
by choosing the association structure that provides the best model performance based on 
some criterion. For instance, returning to the first motivating example introduced in Section 
2, we may believe that risk of death or disease progression for a patient with NSCLC is 
driven by treatment-failure occurring at a single lesion. We may therefore assume the 
hazard of the event for patient 𝑖 at time 𝑡 is associated with the maximum (i.e. largest) of 
the lesion-specific expected values, since this would represent the lesion with the most 
advanced disease, for example due to it having the worst treatment response.   
Moreover, we could easily replace the 𝜇𝑖𝑗(𝑡) in equations (3) through (6) with some other 
function of the longitudinal submodel parameters, such as the level 2 cluster-specific rate of 
change in the marker at time 𝑡 (i.e. 
𝑑𝜇𝑖𝑗(𝑡)
𝑑𝑡
)  or the area under the level 2 cluster-specific 
marker trajectory up to time 𝑡 (i.e. ∫ 𝜇𝑖𝑗(𝑢)
𝑡
0
𝑑𝑢). For instance, we may assume that the 
lesion with largest growth rate may be most informative of treatment failure. Such 
extensions follow naturally from association structures that have been proposed elsewhere 
for shared parameter joint models [11,14]. 
The specifications in equations (3) and (4) both assume a constant magnitude of association 
between the expected value of each level 2 unit and the hazard of the event; that is, there is 
an implicit assumption that the level 2 units within a patient are exchangeable since their 
expectations are each multiplied by the same fixed effect association parameter 𝛼𝑞. It is 
worth noting that this is in contrast to the situation in which we have multiple longitudinal 
biomarkers (for example lesion size and circulating DNA) each measured repeatedly over 
time. In this situation the multiple biomarkers within a patient are not exchangeable and 
therefore each biomarker would have a different coefficient quantifying its association with 
the hazard of the event. Methods for the joint modelling of multiple longitudinal biomarkers 
and time-to-event data, where the multiple biomarkers are not exchangeable, have been 
described elsewhere [11,15,16]. Although it is outside the scope of this paper, the 
methodology described here could be extended to a situation in which we have multiple 
longitudinal biomarkers, some of which may or may not have additional levels of clustering. 
This type of data structure is therefore represented in Figure 1c. 
4. Model estimation 
The joint model proposed in Section 3 can be estimated using the ‘stan_jm’ modelling 
function within the rstanarm R package [17]. The association structure can be based on the 
expected value and/or slope of the longitudinal biomarker, however, currently only a single 
patient-level summary function (summation, average, maximum, or minimum) can be 
chosen by the user (this restriction may be relaxed in a future release). Estimation of the 
model requires a full Bayesian specification with prior distributions on all unknown 
parameters. We provide further details of the estimation (for example prior distributions 
and computation) in the Supplementary Materials. 
5. Application 
We demonstrate the use of our modelling approach by exploring the association between 
tumor burden and the hazard of death or disease progression amongst NSCLC patients 
undergoing treatment. 
5.1 Data 
The Iressa Pan-Asia Study (IPASS) was an open label, phase 3 trial of 1,217 untreated NSCLC 
patients in East Asia randomized to: (i) gefitinib (250mg per day), or (ii) carboplatin (dose 
calculated to provide 5-6 mg per milliliter per minute) plus paclitaxel (200 mg per square 
meter of body-surface area) [18]. The primary endpoint was progression-free survival, 
however, the study was extended to track overall survival in the longer term. We restricted 
our analyses to the 430 (35%) patients with an available test result for epidermal growth 
factor receptor (EGFR) mutation since this has been shown to be associated with both 
tumor dynamics and treatment response [19]. We thereby defined a group covariate 
corresponding to either: (i) EGFR+, (ii) EGFR- and receiving gefitinib; or (iii) EGFR- and 
receiving carboplatin plus paclitaxel. 
5.2 Model specification 
5.2.1 Longitudinal submodel 
We modelled repeated measurements of the longest diameter (in millimetres) of each 
lesion using a linear mixed effects model (identity link, normal distribution) with a linear 
predictor as in equation (1) where:  the observation-level covariates with fixed (population-
average) effects, 𝑥𝑖𝑗(𝑡), included an intercept, the 3-category EGFR-group covariate, linear 
and quadratic terms for time, and an interaction between group and each of the linear and 
quadratic terms for time; the patient-level vector 𝑧𝑖𝑗(𝑡) included an intercept only; and the 
lesion-level vector 𝑤𝑖𝑗(𝑡)included an intercept, and linear and quadratic terms for time. This 
specification allowed for lesion-specific nonlinear (quadratic) evolutions of the longitudinal 
trajectory, while also allowing the average (i.e. population-level) estimate of the nonlinear 
longitudinal trajectory to differ between the three groups (through the group by time 
interaction terms). 
5.2.2 Event submodel 
We modelled the hazard of death or disease progression using the proportional hazards 
model in equation (2). We approximated the log baseline hazard using B-splines with 6 
degrees of freedom and included a 3 category physical functioning measure (normal 
activity; restricted activity; in bed >50% of the time) [20] as a baseline covariate in 𝑣𝑖(𝑡). We 
considered several models which each differed in terms of their association structure. 
Specifically we considered the following: (i) no association structure (i.e. no biomarker 
information in the event submodel), (ii) association structures based on the sum, average, 
maximum or minimum of the lesion-specific expected values (i.e. the association structures 
defined in equations (3) through (6)), and (iii) association structures based on both the 
lesion-specific expected value and slope, that is an association structure of the form 
 ∑ 𝛼𝑞𝑓𝑞(𝛩𝑖𝑗(𝑡))
𝑄
𝑞=1 = 𝛼1 𝑓(𝜇𝑖𝑗(𝑡);  𝑗 = 1, … , 𝐽𝑖) + 𝛼2 𝑓(
𝑑𝜇𝑖𝑗(𝑡)
𝑑𝑡
;  𝑗 = 1, … , 𝐽𝑖)  (7) 
where the function 𝑓(. ) was taken to be either the sum, average, maximum or minimum, 
𝜇𝑖𝑗(𝑡) is the size and 
𝑑𝜇𝑖𝑗(𝑡)
𝑑𝑡
 is the rate of change in the size of lesion 𝑗 in patient 𝑖 at time 𝑡, 
𝐽𝑖  is the total number of target lesions identified for patient 𝑖 at baseline, and 𝛼1 and 𝛼2 are 
association parameters. 
5.3 Model comparison 
An ideal feature of our model would be that it is able to inform clinical decision making by 
accurately predicting a patient’s future risk of death or disease progression in the clinical 
setting. We therefore compared different possible association structures for our proposed 
joint model using a measure of predictive accuracy for the event outcome. Specifically, we 
used the estimated area under the (time-dependent) receiver operating characteristic curve 
(AUC) to assess how well each of the models discriminated between those patients who did 
and did not have the event [3].  
To do this we first used the fitted joint model to generate conditional survival probabilities 
for each patient at some time horizon 𝑡𝐿 + 𝛥𝑡, conditional on: (i) their still being at risk at 
some landmark time 𝑡𝐿, and (ii) their longitudinal biomarker data up to the landmark time 𝑡𝐿 
(following the methods described in [3]). These survival probabilities were then used in 
combination with the observed event times and censoring indicators for each patient, taken 
over the interval (𝑡𝐿 ,  𝑡𝐿 + 𝛥𝑡), to calculate the time-dependent AUC measure. 
5.4 Results 
In our analysis, 360 (84%) of the 430 patients progressed or died prior to censoring. The 
overall Kaplan-Meier curve is shown in Figure 2. There were 1209 lesions across the 430 
patients, and 138 (32%), 101 (23%), 71 (17%) and 120 (28%) patients with 1, 2, 3 or 4+ 
lesions, respectively. A total of 6132 size measurements were observed, corresponding to a 
median number of 5 (IQR: 3 to 7; range: 1 to 17) measurements per lesion. 
Table 1 shows the estimated AUC values for the fitted models. The results are shown for a 
landmark time of 𝑡 = 5 months and a horizon time of 𝑡 + 𝛥𝑡 = 10 months. For an association 
structure based on the expected value (i.e. diameter of the lesion) only, a summary function 
based on the sum or maximum of the lesions showed better discriminatory performance 
compared with using the mean or minimum. We found that also including the slope (i.e. 
rate of change in the diameter of the lesion) in the association structure improved the 
predictive performance. When both the expected value and slope were used in the 
association structure then summaries based on the sum, mean or maximum of the lesions 
all performed similarly. The summary based on the minimum (i.e. size of the smallest lesion, 
and rate of change in the slowest growing lesion, at time 𝑡) was the worst in terms of 
predicting the risk of death or disease progression. These results are in line with what we 
would expect from a clinical perspective, that is, those summaries that incorporate 
information on the largest and/or fastest growing lesion at time 𝑡 are likely to provide 
better predictive performance. This is because they capture information about the most 
aggressive tumor, which may have escaped treatment and is therefore likely to impact most 
severely on the risk of death disease progression and death. 
Table 2 shows the parameter estimates from the model with the best performance based 
on the AUC measure (with an association structure based on the maximum of the lesion-
specific expected values and slopes). The estimated hazard ratio corresponding to the first 
association parameter (i.e. 𝑒𝑥𝑝(𝛼1)) was 1.011 (95% credible interval (CrI): 1.004 to 1.017), 
suggesting that a one millimetre increase in the diameter of a patient’s largest lesion was 
associated with a 1.1% (95% CrI: 0.4 to 1.7%) increase in their hazard of death or disease 
progression (conditional on the other covariates in the model). Similarly, a one millimetre 
per month increase in the rate of change of their fastest growing lesion was associated with 
a 56% (95% CrI: 42 to 75%) increase in their hazard. Figure 3 shows the fitted lesion-specific 
longitudinal trajectories and observed measurements for a selection of patients under the 
fitted model. 
6. Alternative data structure: clustering above the patient-level  
In our analysis of the IPASS data, patient represented the top level of the data hierarchy and 
the additional clustering factor – “lesion” – occurred at a level which was lower in the 
hierarchy than patient; that is, lesions were clustered within patients rather than patients 
being clustered within lesions. An alternative situation is that in which the additional 
clustering factor(s) occur at a level which is higher in the hierarchy than the patient-level. An 
example is where repeated observation times (level 1) exist for patients (level 2) and the 
patients are clustered within clinics (level 3). Another example is an individual patient data 
(IPD) meta-analysis with repeated observation times (level 1) for patients (level 2) clustered 
within randomised clinical trials (level 3) [13].  
Recall however that the event time 𝑇𝑖 is measured at the patient-level and, therefore, the 
patient represents the level of the hierarchy at which our primary interest lies for 
understanding the association between the longitudinal and event processes. For this 
reason, the relative locations within the hierarchy of the patient and the additional 
clustering factor have implications for specifying the association structure of the joint 
model.  
6.1 Model formulations based on a patient-level association structure 
In Section 3.3 we proposed association structures based on a patient-level time-specific 
summary of the 𝐽𝑖  level 2 units clustered within patient 𝑖. However, with clustering above 
the patient-level, there is no need to construct such a patient-level summary.  
Suppose that the longitudinal outcome 𝑦𝑙𝑖𝑘 = 𝑦𝑙𝑖(𝑡𝑙𝑖𝑘) is measured at time point 𝑘 (𝑘 =
1, … , 𝐾𝑙𝑖) which is nested within unit 𝑖 (𝑖 = 1, … , 𝑁𝑙) of the level 2 clustering factor (the 
patient) which in turn is nested within unit 𝑙 (𝑙 = 1, … , 𝐿) of a level 3 clustering factor 
(clinic, say, for example). If we again model the longitudinal outcome in continuous time 
using a generalised linear mixed effects model where 𝑌𝑙𝑖(𝑡) is governed by a distribution in 
the exponential family with expected value 𝜇𝑙𝑖(𝑡) = 𝑔
−1(𝜂𝑙𝑖(𝑡)) we might, for example, 
consider a specification for the longitudinal submodel of the form 
 𝜂𝑙𝑖(𝑡) = 𝑥𝑙𝑖
′ (𝑡)𝛽 + 𝑧𝑙𝑖
′ (𝑡)𝑏𝑙𝑖 + 𝑞𝑙𝑖
′ (𝑡)𝑐𝑙  (8) 
where 𝑥𝑙𝑖(𝑡), 𝑧𝑙𝑖(𝑡) and 𝑞𝑙𝑖(𝑡) are vectors of covariates, possibly time-dependent, 𝑏𝑙𝑖 still 
represents the vector of patient-specific parameters (but now patient 𝑖 is nested within the 
level 3 cluster 𝑙), and 𝑐𝑙 represents the vector of level 3 parameters such that 𝑐𝑙 ∼ 𝑁(0, 𝛴𝑐). 
The corresponding specification of the event submodel may take the form 
 ℎ𝑙𝑖(𝑡) = ℎ0(𝑡)𝑒𝑥𝑝 (𝑣𝑙𝑖
′ (𝑡)𝛾 + 𝛼 𝜇𝑙𝑖(𝑡))   (9) 
Because the additional clustering occurs at a level in the hierarchy that is higher than the 
patient we can simply use an association structure based on the patient-level expected 
value of the longitudinal outcome, without any need to derive a summary quantity based on 
lower-level units. The specification in (9) would assume that the hazard of the event for 
patient 𝑖 at time 𝑡 is associated with the patient-specific expected value of the longitudinal 
marker at time 𝑡, incorporating the effects of any higher level clustering. Note that the 
specification in (9) could be easily extended to any other patient-level function of the 
longitudinal submodel parameters, such as the patient-specific rate of change in the marker 
(i.e. slope) at time 𝑡 or the area under the patient-specific marker trajectory (i.e. integral) up 
to time 𝑡. 
A possible extension would be to include a shared frailty term in the event submodel 
 ℎ𝑙𝑖(𝑡) = ℎ0(𝑡)𝑒𝑥𝑝 (𝑣𝑙𝑖
′ (𝑡)𝛾 + 𝛼 𝜇𝑙𝑖(𝑡) + 𝛿𝑙)  (10) 
where 𝛿𝑙 is, for example, assumed to follow a normal or log-Gamma distribution. The 
inclusion of the shared frailty term does not induce an association with the longitudinal 
submodel, but it does allow for correlation in the event times of patients within a level 3 
cluster. Note that if the variance of the 𝛿𝑙 parameters is close to zero, then this would 
suggest there is little within-cluster correlation in the event times and the shared frailty 
term could be dropped from the model. Moreover, if the number of level 3 groups was 
small then another alternative would be to include the level 3 group as a fixed effect 
covariate in the event submodel or as a stratification factor for the baseline hazard. The 
benefit of these latter models is that they may be computationally simpler than specifying a 
shared frailty term as a random effect. 
6.2 Model formulation based on a higher-level association structure 
An alternative possibility is that the hazard of the event for patient 𝑖 need only be related to 
the higher-level cluster’s deviation from the average. That is, we can consider a shared 
random effects joint model of the form 
 ℎ𝑙𝑖(𝑡) = ℎ0(𝑡)𝑒𝑥𝑝 (𝑣𝑙𝑖
′ (𝑡)𝛾 + 𝛼 𝑐𝑙)   (11) 
where 𝑐𝑙 might, for example, represent the clinic-level random intercept. In this case, we 
would have a model in which we assume that the hazard of the event for patient 𝑖 is 
associated with the way in which their clinic’s biomarker measurements deviate from the 
average clinic, but not with any time-varying characteristics of the patient themselves. Here, 
the random effect 𝑐𝑙 serves two purposes in the event submodel. First, it allows for within-
cluster correlation in the event times (as previously described for the shared frailty). Second, 
it allows for dependence between the event and longitudinal processes through a shared 
parameter at the level of clustering factor 𝑙. 
7. Discussion 
Increasingly complex data structures are being accommodated under a joint longitudinal 
and time-to-event modelling framework. In this paper we have described a new joint 
modelling approach that allows for multilevel hierarchical data, where the data structure 
includes clustering factors beyond that of the individual. Such data structures commonly 
appear in clinical and epidemiological research, however, they have not previously been 
incorporated into a joint modelling framework. Standard joint modelling approaches aim to 
model patient-level measurements of a clinical biomarker, however, greater flexibility can 
be achieved by incorporating both patient-specific and cluster-specific effects in the 
longitudinal submodel when those levels of clustering are present in the underlying data 
structure. Moreover, it allows an additional set of association structures to be used for 
modelling the association between the longitudinal biomarker and the patient-level risk of 
the event. We proposed a set of possible association structures that could be used in most 
settings, however, the most appropriate choice of association structure is likely to depend 
on the primary research question and data structure that is relevant to the application at 
hand. By incorporating the multilevel structure into our joint modelling approach, we are 
able to formulate a model that answers the research question appropriately. For instance, in 
our application, patient-level summaries of the lesion-specific trajectories are likely to be 
meaningful in a way that quantities obtained by ignoring the lesion level would not be.  
A potential limitation of the modelling in our application is that the observed event times 
were subject to interval censoring. This interval censoring is evident from the “steps” that 
can be seen in the Kaplan-Meier curve in Figure 2. This is due to clinicians in the IPASS trial 
declaring disease progression at the scheduled clinic visits. In our application we ignored 
this interval censoring and so an avenue for future work will be to accommodate this 
interval censoring within our proposed joint modelling framework. Moreover, in future 
work, we would like to separately assess the competing event outcomes of death and 
disease progression by considering cause-specific competing risks event submodels. In this 
way, we will be able to separate out the cause-specific associations between tumor burden 
and each of the competing events. 
A significant strength of this paper is that our proposed model, described in Section 3, has 
been implemented as part of the rstanarm R package. A benefit of having implemented this 
model as part of that package is that researchers can easily fit the model to their data, via a 
user-friendly interface with customary R formula syntax and data frames. The back-end 
estimation of the model is carried out under a full Bayesian specification with priors on all 
unknown parameters. A variety of prior distributions are available to the user, as well as a 
variety of exponential family and link function options for the longitudinal outcome, thereby 
providing significant flexibility. In addition, the package allows users to estimate a joint 
model with multiple longitudinal outcomes (i.e. a multivariate joint model) of which one or 
more can have the multilevel structure described in Section 3. We hope that by providing 
user-friendly software and example code (Supplementary Materials) for fitting the proposed 
model, we will help to facilitate its use in a wide variety of applications. 
 
  
References 
1.  Tsiatis AA, Davidian M. JOINT MODELING OF LONGITUDINAL AND TIME-TO-EVENT 
DATA: AN OVERVIEW. Stat Sin. Institute of Statistical Science, Academia Sinica; 2004;14: 
809–834. 
2.  Lawrence Gould A, Boye ME, Crowther MJ, Ibrahim JG, Quartey G, Micallef S, et al. Joint 
modeling of survival and longitudinal non-survival data: current methods and issues. 
Report of the DIA Bayesian joint modeling working group. Stat Med. 2015;34: 2181–
2195. 
3.  Rizopoulos D. Joint Models for Longitudinal and Time-to-Event Data: With Applications 
in R. CRC Press; 2012. 
4.  Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with 
error. Biometrics. 1997;53: 330–339. 
5.  Rizopoulos D. Dynamic predictions and prospective accuracy in joint models for 
longitudinal and time-to-event data. Biometrics. 2011;67: 819–829. 
6.  Taylor JMG, Park Y, Ankerst DP, Proust-Lima C, Williams S, Kestin L, et al. Real-time 
individual predictions of prostate cancer recurrence using joint models. Biometrics. 
2013;69: 206–213. 
7.  Henderson R. Joint modelling of longitudinal measurements and event time data. 
Biostatistics. 2000;1: 465–480. 
8.  Williamson PR, Kolamunnage-Dona R, Philipson P, Marson AG. Joint modelling of 
longitudinal and competing risks data. Stat Med. 2008;27: 6426–6438. 
9.  Gueorguieva R, Rosenheck R, Lin H. Joint modelling of longitudinal outcome and 
interval-censored competing risk dropout in a schizophrenia clinical trial. J R Stat Soc 
Ser A Stat Soc. 2011;175: 417–433. 
10.  Brilleman SL, Crowther MJ, May MT, Gompels M, Abrams KR. Joint longitudinal hurdle 
and time-to-event models: an application related to viral load and duration of the first 
treatment regimen in patients with HIV initiating therapy. Stat Med. 2016;35: 3583–
3594. 
11.  Rizopoulos D, Ghosh P. A Bayesian semiparametric multivariate joint model for multiple 
longitudinal outcomes and a time-to-event. Stat Med. 2011;30: 1366–1380. 
12.  Wu Z, Lin C, Crowther M, Mak H, Yu M, Leung CK-S. Impact of Rates of Change of 
Lamina Cribrosa and Optic Nerve Head Surface Depths on Visual Field Progression in 
Glaucoma. Invest Ophthalmol Vis Sci. 2017;58: 1825–1833. 
13.  Sudell M, Kolamunnage-Dona R, Tudur-Smith C. Joint models for longitudinal and time-
to-event data: a review of reporting quality with a view to meta-analysis. BMC Med Res 
Methodol. 2016;16: 168. 
14.  Andrinopoulou E-R, Rizopoulos D. Bayesian shrinkage approach for a joint model of 
longitudinal and survival outcomes assuming different association structures. Stat Med. 
2016;35: 4813–4823. 
15.  Hickey GL, Philipson P, Jorgensen A, Kolamunnage-Dona R. Joint modelling of time-to-
event and multivariate longitudinal outcomes: recent developments and issues. BMC 
Med Res Methodol. 2016;16: 117. 
16.  Moreno-Betancur M, Carlin JB, Brilleman SL, Tanamas SK, Peeters A, Wolfe R. Survival 
analysis with time-dependent covariates subject to missing data or measurement error: 
Multiple Imputation for Joint Modeling (MIJM). Biostatistics. 2017; 
doi:10.1093/biostatistics/kxx046 
17.  Stan Development Team. rstanarm: Bayesian applied regression modeling via Stan. R 
package version 2.15.4. http://mc-stan.org/. 2016; 
18.  Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or 
Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009;361: 947–
957. 
19.  Fukuoka M, Wu Y-L, Thongprasert S, Sunpaweravong P, Leong S-S, Sriuranpong V, et al. 
Biomarker analyses and final overall survival results from a phase III, randomized, open-
label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected 
patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29: 
2866–2874. 
20.  Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and 
response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5: 
649–656. 
 
  
Figure 1. Example of the hierarchical structure of joint model data under three possible 
scenarios: (a) one longitudinal biomarker (tumor size) where the patient is the only 
clustering factor; (b) one longitudinal biomarker (tumor size) where there are two clustering 
factors (lesions clustered within patients); (c) two longitudinal biomarkers (tumor size and 
circulating DNA), one of which has one clustering factor (the patient), and one of which has 
two clustering factors (lesions clustered within patients). 
 
 
Figure 2. Overall Kaplan-Meier curve for progression-free survival. The values provided at 
the top of the plot are the numbers of patients still at risk for the event. 
 
 
 
Figure 3. Observed longitudinal biomarker measurements (longest diameter of the lesion) 
and the fitted lesion-specific longitudinal trajectories (with 95% prediction intervals) under 
the joint model, for a selection of patients. Each panel of the figure shows a different 
patient, with some patients having multiple lesions. The dashed vertical line shows each 
patient’s event or censoring time. 
 
 
 
  
Table 1. Estimated time-dependent AUC for the proposed joint model using various 
association structures. The AUC is calculated using a landmark time of 𝑡 = 5 months and 
horizon time of 𝑡 = 10 months.  
Association structure Time-dependent AUC 
No biomarker data (i.e. no association structure) 0.50 
  
Lesion-specific value  
  Sum 0.62 
  Average 0.56 
  Maximum 0.61 
  Minimum 0.55 
  
Lesion-specific value & slope  
  Sum 0.65 
  Average 0.64 
  Maximum 0.66 
  Minimum 0.59 
Abbreviations. AUC: area under the (receiver operating characteristic) curve. 
  
Table 2. Fixed effect parameter estimates (posterior means and 95% credible interval limits) 
from the joint model. The estimates for the event submodel are hazard ratios and the 
coefficients for the B-splines baseline hazard have been omitted. 
Parameter Estimate Lower Upper 
Longitudinal submodel    
   Intercept 23.0 21.3 24.7 
   Group (ref: EGFR+)    
       EGFR-, carboplatin plus paclitaxel 4.0 0.8 7.1 
       EGFR-, gefitinib 16.9 13.2 20.4 
   Time effects    
       Linear term (orthogonalised) -0.1 -73.3 76.7 
       Quadratic term (orthogonalised) 450.3 391.6 512.5 
   Group * Linear interaction    
      EGFR-, carboplatin plus paclitaxel * Linear 315.2 195.1 438.4 
      EGFR-, gefitinib * Linear 390.0 127.5 660.4 
   Group * Quadratic interaction    
      EGFR-, carboplatin plus paclitaxel * Quadratic 23.7 -74.3 123.4 
      EGFR-, gefitinib * Quadratic -524.8 -697.0 -351.1 
    
Event submodel    
   Physical functioning (ref: in bed >50% of the time)    
       Normal activity 0.6 0.4 1.0 
       Restricted activity 0.6 0.4 1.0 
   Association parameters (exponentiated)    
       Value (diameter of largest lesion at time 𝑡) 1.011 1.004 1.017 
       Slope (rate of change in fastest growing lesion at time 𝑡) 1.56 1.42 1.75 
Abbreviations. ref: reference category; EGFR: epidermal growth factor receptor (mutation 
status).
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1. Further details on the model estimation 
Our Bayesian specification requires prior distributions on all unknown parameters. We refer 
the reader to the documentation of the rstanarm R package for details on prior 
distributions, since our model was estimated using default priors implemented in the 
package. In brief, we used weakly informative normal distributions for each of the 
regression coefficients (fixed effects). The residual standard deviation (for the longitudinal 
outcome) was given a weakly informative half-Cauchy distribution. The B-spline coefficients 
for the log baseline hazard were given weakly informative Cauchy distributions. The weakly 
informative priors were only intended to reduce support given to values of the parameters 
that would seem implausible based on the scale of magnitude of the data. They were not 
intended to provide support to specific parameter values based on prior knowledge or 
expert opinion.  
For estimation of the model parameters we ran four MCMC chains in parallel, each with 
1000 sample iterations preceded by a warm up period of 1000 iterations (i.e. 2000 iterations 
in total, of which 50% were warm up). Although this number of iterations would seem small 
for a complex model estimated using a Gibbs sampler, the estimation in Stan is based on a 
Hamiltonian Monte Carlo (HMC) algorithm, not Gibbs sampling. The HMC results in much 
lower autocorrelation between subsequent MCMC draws compared with Gibbs sampling, 
and therefore is much more efficient in terms of the effective sample size per iteration. For 
example, for each of the models with an association structure based on the expected value, 
the effective sample size for the estimated association parameter was 4000. 
A potential limitation of the proposed approach is the additional computational complexity. 
Additional clustering factors mean that there are an increasing number of cluster-specific 
parameters (i.e. random effects) to be estimated and therefore computation time increases. 
In our application with 430 patients having a total of 1209 lesions, there were 430 patient-
specific parameters (intercept only) and 3627 lesion-specific parameters (intercept and two 
polynomial terms) to be estimated. Computation time for the models with an association 
structure based on the expected value ranged between 1.5 and 3 hours. The differences in 
computation time were partly related to the random nature of the different MCMC chains, 
and partly related to the type of summary function used in the association structure (i.e. the 
sum, average, maximum, or minimum of the level 2 clusters). The type of association 
structure is of course part of the model definition and therefore the choice of association 
structure will have an influence on the shape of the target posterior distribution, with some 
resulting posteriors easier for the MCMC sampler to explore (i.e. less extreme curvature in 
the posterior). When the association structure was based on both the expected value and 
the slope, the computation times were slightly longer; ranging between 2 and 5.5 hours. 
These times are based on 1000 warm up iterations, followed by 1000 sample iterations, on a 
standard quad-core desktop with a 3.30GHz processor and 8GB RAM.  
2. Example code for fitting the model 
The model in the paper can be easily estimated after downloading the rstanarm R package 
from the Comprehensive R Archive Network (CRAN). To download and install rstanarm, type 
the following into your R console: 
  > install.packages("rstanarm") 
And then an example of the code used to fit the model presented in Table 2 of the main 
manuscript would be: 
  > library(rstanarm) 
  > mod <- stan_jm( 
    formulaLong = ldiam ~  
      cat * poly(months, degree = 2) + 
      (poly(months, degree = 2) | lesid_usubjid) +  
      (1 | usubjid),  
    dataLong = ipass$lesions, 
    formulaEvent = Surv(progmnth, censor_p) ~ whostat,  
    dataEvent = ipass$surv, 
    seed = 9837355, time_var = "months", id_var = "usubjid", 
    assoc = c("etavalue", "etaslope"), grp_assoc = "max") 
Where ipass$lesions is a data frame containing the outcome and covariate data for the 
longitudinal submodel, and ipass$surv is a data frame containing the outcome and 
covariate data for the event submodel. Unfortunately, since the IPASS data used in the 
application in the main manuscript is not publically available, we cannot provide the 
reader with these data frames. 
 
 
 
